

340B Helps Wisconsin Communities

The 340B Prescription Drug Discount Program helps hospitals extend care!

Wisconsin hospitals use 340B savings to benefit their local communities by expanding access to important health care services, including:



Low-cost or free dental clinics



Low-cost or free health care clinics



Behavioral health services



RX remote dispensing sites for rural areas

340B



Does not cost taxpayers, employers, or insurers a dime because it is funded by drug manufacturer discounts.



Is one of the few tools hospitals have to offset skyrocketing drug costs.



Saves Taxpayers money by lowering costs for Critical Access Hospitals.

Program Integrity



Hospitals devote significant resources toward complying with federal 340B requirements.

WHA Staff Contact: Jon Hoelter
jhoelter@wha.org



And yet, large drug companies continue to deny required 340B discounts at community pharmacies hospitals contract with to dispense medications.



Meanwhile Pharmacy Benefit Manager middlemen have created policies that allow them to pocket 340B savings Congress intended to go to hospitals.

Drugmakers' Actions are Harming 340B Hospitals



*Numbers provided from November 2022 AHA Report

Congress must pass the Sustain 340B Act to protect 340B hospitals from predatory actions of drugmakers and PBMs.

Get the Facts on 340B

What drugmakers don't want you to know...

340B GROWTH?

While drugmakers decry the supposed “unchecked growth of 340B,” in reality, more than half of 340B growth is a direct result of drug makers intentionally raising drug prices faster than inflation, which increases the discounts 340B drugs are subject to.



PAY FOR DELAY

The Federal Trade Commission estimates the cost of drug companies’ “pay for delay” schemes at \$3.5 billion annually - these schemes use a complex web of patents to preserve drug monopolies - or even direct payments to competitors to delay bringing new generics into the market.

MARKETING \$\$\$

Though less than 2% of the U.S. uses a specialty drug, it accounts for more than half of the total U.S. drug market. Its high-margin value has also led to significant growth in marketing - with the drug Rinvoq alone having sales of \$2.5 billion and nearly \$426 million in marketing in 2022 - nearly double its marketing from the year before.

Drug companies are casting aspersions on 340B to deflect criticism from their own actions that are raising prices on consumers and generating enormous profits for them.



How can lawmakers help?

A bipartisan gang of 6 senators including Sens. Moran, Baldwin, Capito, Kaine, Mullin, and Hickenlooper continue work on last session's draft legislation known as the SUSTAIN 340B Act.

The legislation would fix contract pharmacy restrictions and end discriminatory PBM reimbursement. Congress should work quickly to introduce this important legislation to fix aspects of 340B that PhRMA and PBMs have broken.